Epcoritamab delivered encouraging efficacy data and a favourable safety profile in participants with high-risk Richter’s transformation (RT).
Mitapivat improved Hb levels and fatigue in participants with non-transfusion-dependent alpha or beta thalassaemia (NTDT) in a phase 3 study.
Treatment with pelabresib plus ruxolitinib was associated with improvements in all 4 hallmarks of myelofibrosis, the phase 3 MANIFEST-2 trial showed.
JAK inhibitor-naïve participants with myelofibrosis benefitted from a regimen of navitoclax plus ruxolitinib compared with ruxolitinib and a placebo.
The intestinal microbiome is essential in many body processes. Could prebiotic food intake benefit intestinal flora in intestinal polyps or colorectal carcinoma?
Anitocabtagene autoleucel (anito-cel) yielded excellent efficacy results in heavily pre-treated participants with relapsed or refractory multiple myeloma.
Isatuximab with bortezomib, lenalidomide + dexamethasone yielded better outcomes than VRd alone for first-line treatment of transplant-ineligible cases.
Treatment led to high measurable residual disease-negativity rates in European LeukaemiaNet subgroups for newly-diagnosed acute myeloid leukaemia.
The combination delivered a high rate of durable complete metabolic responses regardless of cell of origin in aggressive B-cell lymphoma patients.
Acalabrutinib added to bendamustine and rituximab decreased disease progression or death risks compared with BR and a placebo for mantle cell lymphoma.
An AI algorithm called "Sturgeon" can classify CNS tumours fast and accurately during surgery. This enables resection strategies adapted to tumour types.
Belantamab mafodotin plus pomalidomide and dexamethasone PVd for progression-free survival in participants with relapsed or refractory multiple myeloma.
High-risk diffuse large B-cell lymphoma patients with a complete metabolic response (CMR) after R-CHOP benefitted from atezolizumab consolidation therapy.
All-Trans Retinoic Acid plus Arsenic Trioxide was superior to ATRA-chemotherapy in event-free survival high-risk acute promyelocytic leukaemia.
Future hepatologists could have numerous drugs for MASLD control and treatment. Promising results from recent trials were presented at EASL 2024.
During EASL 2024, the rise of AI in radiology and liver pathology; and of multisystem / multiscale integration in HCC patient care was discussed.
AI is revolutionizing many fields, including hepatology. During EASL 2024, its clinical application was discussed, with a focus on personalized patient management.
Which diagnostic and treatment pathways for MASLD patients will exist in 2030? Dr. Ian Rowe discusses patient management scenarios in the near future.
A symposium addressed chronic viral hepatitis management in children, and whether all children with chronic viral hepatitis should be treated.
Liver diseases expert Prof. Umberto Vespasiani-Gentilucci addresses important innovations in disease management with a focus on PBC and ‘real world’ data use.